Moderna Inc (NAS:MRNA)
$ 131.25 -1.43 (-1.08%) Market Cap: 50.30 Bil Enterprise Value: 43.56 Bil PE Ratio: 0 PB Ratio: 3.92 GF Score: 68/100

Moderna Inc Corporate Analyst Meeting Transcript

Sep 12, 2019 / 12:30PM GMT
Release Date Price: $16.4 (+3.02%)
StÃ;phane Bancel
Moderna, Inc. - CEO & Director

© -

Good morning. Welcome to Moderna's third annual R&D meeting. Thank you for joining us in person in the room. And for those of you joining us via webcast, thanks for joining in. We're very pleased to host you today and to share some interesting new data about Moderna's platform that are important for patients.

Before we start, let me remind you, we'll be making forward-looking statements that make mRNA to be a risky endeavor. And I invite you to check our risk factors on the SEC website or on the Moderna website.

As many of you know, since we started the company, we thought that mRNA could be a very powerful new potential class of medicine. What excited us is the possibility of doing not only secreted protein but also intracellular and transmembrane. And when you think that the majority of a protein encoded in the human genome are coded for transmembrane and intracellular protein, there could be a very large possibility to help patients.

We believe because mRNA is an information molecule that we'll have a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot